AtriCure, Inc. (NASDAQ:ATRC) Shares Acquired by Truist Financial Corp

Truist Financial Corp increased its holdings in AtriCure, Inc. (NASDAQ:ATRC – Get Rating) by 6.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 26,597 shares of the medical device company’s stock after buying an additional 1,574 shares during the period. Truist Financial Corp’s holdings in AtriCure were worth $1,041,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of the business. PNC Financial Services Group Inc. lifted its position in AtriCure by 47.7% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,975 shares of the medical device company’s stock valued at $392,000 after purchasing an additional 1,931 shares during the last quarter. AlphaCrest Capital Management LLC bought a new stake in AtriCure in the 1st quarter valued at about $343,000. MetLife Investment Management LLC lifted its position in AtriCure by 54.8% in the 1st quarter. MetLife Investment Management LLC now owns 24,141 shares of the medical device company’s stock valued at $1,585,000 after purchasing an additional 8,549 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in AtriCure by 7.0% in the 1st quarter. Dimensional Fund Advisors LP now owns 717,125 shares of the medical device company’s stock valued at $47,092,000 after purchasing an additional 46,705 shares during the last quarter. Finally, Sei Investments Co. lifted its position in AtriCure by 0.5% in the 1st quarter. Sei Investments Co. now owns 94,103 shares of the medical device company’s stock valued at $6,182,000 after purchasing an additional 461 shares during the last quarter. 95.27% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

ATRC has been the topic of several recent research reports. BTIG Research cut their price objective on shares of AtriCure from $75.00 to $71.00 and set a “buy” rating on the stock in a research report on Monday, October 17th. StockNews.com upgraded shares of AtriCure from a “sell” rating to a “hold” rating in a research report on Tuesday, January 10th. Canaccord Genuity Group dropped their price target on shares of AtriCure from $72.00 to $65.00 in a research report on Wednesday, November 2nd. Canaccord Genuity Group dropped their price target on shares of AtriCure from $72.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 2nd. Finally, TheStreet downgraded shares of AtriCure from a “c-” rating to a “d” rating in a research report on Tuesday, November 1st. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, AtriCure has an average rating of “Moderate Buy” and a consensus target price of $60.67.

AtriCure Stock Down 0.9 %

NASDAQ ATRC opened at $42.07 on Friday. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.69 and a quick ratio of 2.92. The company’s 50 day simple moving average is $44.12 and its 200 day simple moving average is $43.76. AtriCure, Inc. has a 12 month low of $32.51 and a 12 month high of $72.31. The company has a market capitalization of $1.96 billion, a P/E ratio of -34.48 and a beta of 1.24.

AtriCure (NASDAQ:ATRC – Get Rating) last released its earnings results on Tuesday, November 1st. The medical device company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.02). AtriCure had a negative return on equity of 12.09% and a negative net margin of 17.76%. The business had revenue of $83.25 million during the quarter, compared to the consensus estimate of $81.40 million. Equities research analysts expect that AtriCure, Inc. will post -1.1 earnings per share for the current fiscal year.

AtriCure Profile

(Get Rating)

AtriCure, Inc develops, manufactures, and sells devices for the surgical ablation of cardiac tissue and systems, and intercostal nerves to medical centers in the United States, Europe, Asia, and internationally. The company offers Isolator Synergy Clamps, a single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation and ablate cardiac tissue with the same device; and the Coolrail device, which enable users to make longer linear lines of ablation.